1033739-92-2 Usage
Uses
Used in Oncology:
GNE-490 is used as an anti-cancer agent for its ability to inhibit the ERBB3 protein kinase receptor, which is implicated in the promotion of tumor growth and progression in various cancer types. Its application is particularly relevant for cancers driven by the overexpression or dysregulation of ERBB3 signaling.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, GNE-490 is utilized as a subject of research and development for the creation of targeted cancer therapies. Its selectivity for ERBB3 and demonstrated anti-tumor activity in preclinical studies make it a valuable compound for further investigation into its potential as a cancer treatment.
Used in Clinical Trials:
GNE-490 is expected to be used in clinical trials to evaluate its safety and efficacy in human patients. These trials are crucial for determining the appropriate dosing, potential side effects, and overall therapeutic value of GNE-490 as a cancer treatment option.
Used in Drug Formulation Development:
In the field of drug formulation, GNE-490 may be used to develop new pharmaceutical formulations that enhance its delivery, bioavailability, and therapeutic effectiveness. This could involve the design of novel drug delivery systems or combination therapies to maximize the compound's potential as a cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1033739-92-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,7,3 and 9 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1033739-92:
(9*1)+(8*0)+(7*3)+(6*3)+(5*7)+(4*3)+(3*9)+(2*9)+(1*2)=142
142 % 10 = 2
So 1033739-92-2 is a valid CAS Registry Number.
1033739-92-2Relevant academic research and scientific papers
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available Pan-PI3-kinase and dual Pan-PI3-kinase/mTOR inhibitors for the treatment of cancer
Sutherlin, Daniel P.,Sampath, Deepak,Berry, Megan,Castanedo, Georgette,Chang, Zhigang,Chuckowree, Irina,Dotson, Jenna,Folkes, Adrian,Friedman, Lori,Goldsmith, Richard,Heffron, Tim,Lee, Leslie,Lesnick, John,Lewis, Cristina,Mathieu, Simon,Nonomiya, Jim,Olivero, Alan,Pang, Jodie,Prior, Wei Wei,Salphati, Laurent,Sideris, Steve,Tian, Qingping,Tsui, Vickie,Wan, Nan Chi,Wang, Shumei,Wiesmann, Christian,Wong, Susan,Zhu, Bing-Yan
experimental part, p. 1086 - 1097 (2010/08/05)
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural in
